James Waldron

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity.

Alpha-9 Oncology has raised a

Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies in quick succession, the biotechs have finally decided to part ways.

Not content with getting the first lupus drug to market in the form of the blockbuster Benlysta more than a decade ago, GSK is handing over $300 million in upfront cash for a clinical-stage T-cell

Innovent has posted another psoriasis win for its IL-23 contender to the likes of Tremfya and

Pfizer's respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, leading the biotech to terminate the study,

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies.